Is Besponsa included in China’s medical insurance?

Besponsa oxalican Leukemia, B-ALL). It is a monoclonal antibody drug whose mechanism of action is to interfere with the growth and survival of leukemia cells by targeting the CD22 antigen on the surface of lymphocytes.

Ogaintuzumab/Ointuzumab is not included in the medical insurance. Ointuzumab/Ointuzumab has been launched in China, but it is not included in the medical insurance. The domestic price is around 60,000 to 70,000 yuan, which is very expensive. Patients can buy it domestically. There are only original drugs available abroad, mainly Pfizer’s original drugs, which cost more than 80,000 yuan.

B-ALL is a rare but severe type of leukemia that usually occurs in adults, especially those who have become resistant to traditional treatments or have relapsed. Oplusintuzumab/The introduction of intuzumab provides a new treatment option for these patients.

The drug's targeting properties allow it to selectively interfere with B-ALL patients' leukemia cells without damaging normal cells. Ogaintozumab/OintozumabRepresents an innovation in the field of leukemia treatment and is expected to improve patient survival rates and quality of life. However, patients should receive treatment under the supervision of a physician to ensure safe and effective use of the drug.

Patients taking oxinuximab/oxinuximab should inform their doctors about all other drugs they are taking because there may be a risk of drug interactions. Ogaintuzumab/OintuzumabIt may cause a variety of side effects, including fever, infection, anemia, bleeding tendencies, nausea and vomiting, abnormal liver function, headache, gastrointestinal discomfort, skin reactions, neurological symptoms, and immune-related adverse reactions. Patients require close monitoring and regular follow-up with their doctor during treatment to ensure the effectiveness and safety of the treatment.